MedDataX Logo

Liver Transplant CGM

NCT ID: NCT07216508

Last Updated: 2025-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-13

Study Completion Date

2027-10-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This investigator initiated study aims to describe continuous glucose monitoring (CGM) based glycemic metrics after discharge from liver transplant and assess relationship with glycemic metrics and liver transplant outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Liver transplant participants will be recruited. Participants will wear a blinded sensor after hospital discharge for up to 30 days. Data can be shared with participant and the providers retrospectively. Participants will be invited to wear another blinded sensor at 6 and 12 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplant Post Transplant Diabetes Type 2 Diabetes

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

liver transplant hyperglycemia diabetes continuous glucose monitoring glucose sensor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants post liver transplant

Participants who are discharged from after liver transplant.

Libre 3+

Intervention Type DEVICE

Blinded CGM will be worn by all participants

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Libre 3+

Blinded CGM will be worn by all participants

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

blinded CGM

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• inpatient liver transplant participants who have had an inpatient glucose greater than 180mg/dL

Exclusion Criteria

* having a planned discharge to a rehabilitation or nursing facility,
* a contraindication to sensor placement,
* if discharge is anticipated to be \>30 days post-transplant, or
* if recent transplant also included a kidney or pancreas transplant
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Icahn School of Medicine at Mount Sinai

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Grenye O'Malley

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Grenye O'Malley, MD

Role: PRINCIPAL_INVESTIGATOR

Icahn School of Medicine at Mount Sinai

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mount Sinai Hospital

New York, New York, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Grenye O'Malley

Role: CONTACT

Phone: 212-241-7173

Email: grenye.o'[email protected]

Alexa Brett

Role: CONTACT

Phone: 212-241-7586

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Grenye O'Malley, MD

Role: primary

Alexa Brett

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STUDY-24-01098

Identifier Type: -

Identifier Source: org_study_id